Prostate Cancer Diagnostics Market (2026-2036)

The prostate cancer diagnostics market covers prostate specific antigen and derivative blood tests, blood and urine risk biomarker tests, multiparametric and biparametric magnetic resonance imaging, prostate specific membrane antigen positron emission tomography, histopathology, and genomic and tissue-based classifiers, together with the reading and reporting supplied with them. The growth of this market is driven by imaging placed before biopsy, by risk biomarkers deciding who needs further investigation, by genomic classifiers separating indolent from aggressive disease, and by programme evaluation now under way in Europe.

The United States Preventive Services Task Force recommendation dated 8 May 2018, which the task force lists as under update, gives prostate specific antigen based screening in men aged 55 to 69 a grade C, stating that the decision should be an individual one taken after discussion of benefits and harms with a clinician, and gives screening in men aged 70 and older a grade D, recommending against it. The task force recorded that screening may prevent about 1.3 prostate cancer deaths and about 3 cases of metastatic cancer per 1,000 men screened over about 13 years with no reduction in all-cause mortality, against harms including more than 15% of men in one trial having at least one false-positive result over 10 years, biopsy complications requiring hospitalisation after about 1% of biopsies, 20% to 50% of screen-detected cancers possibly being overdiagnosed, long-term urinary incontinence in about 1 in 5 men after radical prostatectomy and long-term erectile dysfunction in about 2 in 3 after prostatectomy and more than half after radiation. Prostate cancer is therefore the one major cancer in which the task force declines to recommend population screening, and the reason recorded is quantified harm rather than absent benefit.

Every growth segment in this market exists to reduce one of those harms rather than to find more cancer. Imaging before biopsy avoids biopsies, risk biomarkers decide who needs imaging or biopsy at all, genomic classifiers separate disease that requires treatment from disease that does not, and accurate staging avoids treating men whose cancer has already spread. The commercial opportunity is consequently defined by the harm figures rather than by the detection rate.

Prostate cancer presents a problem that the other common cancers do not, because a substantial proportion of the disease detected would never have caused symptoms or death. Finding it therefore does not reliably benefit the man in whom it is found, and the pathway from an elevated blood test to a treatment decision contains several points at which detection without benefit becomes harm.

The United States Preventive Services Task Force recommendation dated 8 May 2018, which the task force lists as under update, gives prostate specific antigen based screening in men aged 55 to 69 a grade C, stating that the decision should be an individual one taken after discussion of benefits and harms with a clinician, and gives screening in men aged 70 and older a grade D, recommending against it. The task force recorded that screening may prevent about 1.3 prostate cancer deaths and about 3 cases of metastatic cancer per 1,000 men screened over about 13 years with no reduction in all-cause mortality, against harms including more than 15% of men in one trial having at least one false-positive result over 10 years, biopsy complications requiring hospitalisation after about 1% of biopsies, 20% to 50% of screen-detected cancers possibly being overdiagnosed, long-term urinary incontinence in about 1 in 5 men after radical prostatectomy and long-term erectile dysfunction in about 2 in 3 after prostatectomy and more than half after radiation. A recommendation that screening be an individual decision rather than a programme offer follows directly from those figures, and no amount of improvement in a blood test alters them, because the problem is what happens after a positive result rather than how accurately the result is obtained.

Magnetic resonance imaging placed before biopsy rather than after it changed the pathway more than any biomarker has. An image showing no suspicious lesion allows a biopsy to be avoided, and an image showing one allows the biopsy to be directed at it rather than sampled blindly, which both reduces the number of biopsies performed and raises the proportion of clinically significant disease found in those that are. That is a direct reduction in two of the recorded harms rather than an improvement in detection.

Risk biomarkers sit earlier again, between the blood test and the imaging. A test combining prostate specific antigen with other analytes, or measuring gene expression in urine, estimates the probability that clinically significant cancer is present and therefore whether imaging or biopsy is warranted at all. Each such test is sold on the procedures it avoids rather than on the cancers it finds, which is an unusual commercial proposition in oncology diagnostics and follows from the harm profile.

A man with low or intermediate grade disease faces a choice between surveillance and treatment, and treatment carries long-term urinary incontinence in about 1 in 5 after radical prostatectomy and long-term erectile dysfunction in about 2 in 3, so a test estimating whether his particular tumour is likely to progress informs the decision that produces most of the harm in the pathway.

Prostate specific membrane antigen imaging has moved staging from inference to measurement, since the receptor is expressed on most prostate cancer cells and a positron emission tomography tracer bound to it identifies disease that conventional imaging does not. Accurate staging prevents radical local treatment in men whose disease has already spread and identifies men whose recurrence can still be treated locally, and the same target now also directs radioligand therapy, which links the diagnostic and therapeutic decisions.

The Council of the European Union adopted a new approach to cancer screening on 9 December 2022 which does not establish prostate screening outright but asks Member States, on the basis of further research, to evaluate the feasibility and effectiveness of organised prostate cancer screening for men, naming prostate specific antigen testing with magnetic resonance imaging as the follow-up, within a stepwise approach extending screening to prostate, lung and, in certain circumstances, gastric cancer. A request to evaluate feasibility and effectiveness rather than to implement reflects the same harm profile, and it names the two-step pathway of a blood test followed by imaging rather than a blood test alone, which is the arrangement intended to contain overdiagnosis.

The TRANSFORM trial began inviting men on 21 November 2025, a GBP 42 million study co-led by University College London and funded with GBP 16 million from the National Institute for Health and Care Research and GBP 26 million from Prostate Cancer UK, comparing prostate specific antigen blood tests, genetic saliva tests and fast magnetic resonance imaging scans alone and in combination against the current National Health Service diagnostic pathway in a first-stage cohort of 16,000 men before testing the most effective approaches in up to 300,000, with men aged 50 to 74 eligible and from 45 for some groups including Black men, invited by letter rather than volunteering, and with results capable of informing the decision on whether to introduce prostate cancer screening. A trial of that size comparing a blood test, a saliva test and a fast scan alone and in combination against the existing pathway is designed to establish which arrangement finds the cancers that matter without the harms that stopped screening being recommended, which is the question the whole market turns on.

Active surveillance rather than treatment is now the standard management for low-risk disease, and it generates recurring diagnostic demand of its own. A man under surveillance undergoes periodic blood tests, imaging and sometimes repeat biopsy for years, so each man managed that way consumes more diagnostics over time than a man treated immediately, which is one of the few circumstances in which avoiding treatment increases diagnostic revenue.

Men of African ancestry carry materially higher incidence and mortality and present younger, which is why the United Kingdom trial opens eligibility from 45 for that group rather than 50. Risk-adapted pathways that begin earlier or test more frequently in higher-risk groups are therefore a clinical requirement as much as a commercial opportunity, and they depend on recorded family history and ancestry that health systems hold inconsistently.